MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder

Wingerchuk, 2015, International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology, 85, 177, 10.1212/WNL.0000000000001729

Lennon, 2004, A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis, Lancet, 364, 2106, 10.1016/S0140-6736(04)17551-X

Lennon, 2005, IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel, J Exp Med, 202, 473, 10.1084/jem.20050304

Marignier, 2013, Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity, Neurology, 80, 2194, 10.1212/WNL.0b013e318296e917

Sato, 2014, Seronegative neuromyelitis optica spectrum – the challenges on disease definition and pathogenesis, Arq Neuropsiquiatr, 72, 445, 10.1590/0004-282X20140032

Zekeridou, 2015, Aquaporin-4 autoimmunity, Neurol Neuroimmunol Neuroinflamm, 2, e110, 10.1212/NXI.0000000000000110

Bernard-Valnet, 2015, Neuromyelitis optica: a positive appraisal of seronegative cases, Eur J Neurol, 22, e82, 10.1111/ene.12679

Kitley, 2012, Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype, Neurology, 79, 1273, 10.1212/WNL.0b013e31826aac4e

Mader, 2011, Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders, J Neuroinflamm, 8, 184, 10.1186/1742-2094-8-184

Sepúlveda, 2016, Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes, J Neurol, 263, 1349, 10.1007/s00415-016-8147-7

Jarius, 2016, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome, J Neuroinflamm, 13, 280, 10.1186/s12974-016-0718-0

Jurynczyk, 2017, Clinical presentation and prognosis in MOG-antibody disease: a UK study, Brain, 140, 3128, 10.1093/brain/awx276

Ramanathan, 2018, Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination, J Neurol Neurosurg Psychiatry, 89, 127, 10.1136/jnnp-2017-316880

McLaughlin, 2009, Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis, J Immunol, 183, 4067, 10.4049/jimmunol.0801888

Brilot, 2009, Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease, Ann Neurol, 66, 833, 10.1002/ana.21916

Wang, 2016, Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD, Neurology, 87, 229, 10.1212/WNL.0000000000002844

Ogawa, 2017, MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy, Neurol Neuroimmunol Neuroinflamm, 4, e322, 10.1212/NXI.0000000000000322

Fujimori, 2017, Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies, J Neurol Neurosurg Psychiatry, 88, 534, 10.1136/jnnp-2016-315094

Hamid, 2018, Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease, JAMA Neurol, 75, 65, 10.1001/jamaneurol.2017.3196

Fukushima, 2017, A case of anti-MOG antibody-positive multiphasic disseminated encephalomyelitis co-occurring with unilateral cerebral cortical encephalitis, Rinsho Shinkeigaku, 57, 723, 10.5692/clinicalneurol.cn-001078

Spadaro, 2015, Histopathology and clinical course of MOG-antibody-associated encephalomyelitis, Ann Clin Transl Neurol, 2, 295, 10.1002/acn3.164

Johns, 1999, The structure and function of myelin oligodendrocyte glycoprotein, J Neurochem, 72, 1, 10.1046/j.1471-4159.1999.0720001.x

Johns, 1997, Binding of complement component Clq to myelin oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation, Mol Immunol, 34, 33, 10.1016/S0161-5890(97)00005-9

Mayer, 2012, Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more, Ther Adv Neurol Disord, 5, 147, 10.1177/1756285611433772

Weissert, 2002, High immunogenicity of intracellular myelin oligodendrocyte glycoprotein epitopes, J Immunol, 169, 548, 10.4049/jimmunol.169.1.548

Peschl, 2017, Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases, Front Immunol, 8, 529, 10.3389/fimmu.2017.00529

Iglesias, 2001, T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis, Glia, 36, 220, 10.1002/glia.1111

Adelmann, 1995, The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat, J Neuroimmunol, 63, 17, 10.1016/0165-5728(95)00124-7

Sakuma, 2004, Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW.1AV1 rats, Brain, 127, 2201, 10.1093/brain/awh260

Storch, 1998, Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology, Brain Pathol, 8, 681, 10.1111/j.1750-3639.1998.tb00194.x

Bettelli, 2003, Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis, J Exp Med, 197, 1073, 10.1084/jem.20021603

Bettelli, 2006, Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice, J Clin Invest, 116, 2393, 10.1172/JCI28334

Krishnamoorthy, 2006, Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation, J Clin Invest, 116, 2385, 10.1172/JCI28330

Dale, 2014, Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton, Neurol Neuroimmunol Neuroinflamm, 1, e12, 10.1212/NXI.0000000000000012

Fujihara, 2012, Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease, Clin Exp Neuroimmunol, 3, 58, 10.1111/j.1759-1961.2012.00030.x

Ikeda, 2015, Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody, Mult Scler J, 21, 656, 10.1177/1352458514551455

Kaneko, 2016, Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies, J Neurol Neurosurg Psychiatry, 87, 1257, 10.1136/jnnp-2015-312676

Zamvil, 2015, Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?, Neurol Neuroimmunol Neuroinflamm, 2, e62, 10.1212/NXI.0000000000000062

Zhou, 2017, MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients, J Neuroimmunol, 305, 19, 10.1016/j.jneuroim.2017.01.007

Körtvélyessy, 2017, ADEM-like presentation, anti-MOG antibodies, and MS pathology: two case reports, Neurol Neuroimmunol Neuroinflamm, 4, e335, 10.1212/NXI.0000000000000335

Jarius, 2016, Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in “pattern II multiple sclerosis” and brain biopsy findings in a MOG-IgG-positive case, Mult Scler J, 22, 1541, 10.1177/1352458515622986

Lucchinetti, 2000, Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination, Ann Neurol, 47, 707, 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q

Di Pauli, 2015, Fulminant demyelinating encephalomyelitis, Neurol Neuroimmunol Neuroinflamm, 2, e175, 10.1212/NXI.0000000000000175

Brehm, 1999, Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG), J Neuroimmunol, 97, 9, 10.1016/S0165-5728(99)00010-7

von Büdingen, 2004, Frontline: epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination, Eur J Immunol, 34, 2072, 10.1002/eji.200425050

O’Connor, 2007, Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein, Nat Med, 13, 211, 10.1038/nm1488

Spadaro, 2015, Detection of autoantibodies against myelin oligodendrocyte glycoprotein in multiple sclerosis and related diseases, Methods Mol Biol, 1304, 99, 10.1007/7651_2015_223

Sato, 2014, Distinction between MOG antibody positive and AQP4 antibody-positive NMO spectrum disorders, Neurology, 82, 474, 10.1212/WNL.0000000000000101

Kitley, 2014, Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study, JAMA Neurol, 71, 1, 10.1001/jamaneurol.2013.5857

Höftberger, 2014, Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease, Mult Scler, 21, 866, 10.1177/1352458514555785

van Pelt, 2015, Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands, Eur J Neurol, 23, 580, 10.1111/ene.12898

Rostasy, 2012, Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis, Arch Neurol, 69, 752, 10.1001/archneurol.2011.2956

Rostásy, 2013, Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica, Mult Scler, 19, 1052, 10.1177/1352458512470310

Ramanathan, 2014, Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis, Neurol Neuroimmunol Neuroinflamm, 1, e40, 10.1212/NXI.0000000000000040

Chalmoukou, 2015, Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis, Neurol Neuroimmunol Neuroinflamm, 2, e131, 10.1212/NXI.0000000000000131

Cobo-Calvo, 2015, Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications, Mult Scler, 22, 312, 10.1177/1352458515591071

Hyun, 2015, Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis, Mult Scler, 21, 710, 10.1177/1352458514551454

Kim, 2015, Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS, Neurol Neuroimmunol Neuroinflamm, 2, e163, 10.1212/NXI.0000000000000163

Pröbstel, 2015, Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype, J Neuroinflamm, 12, 1, 10.1186/s12974-015-0256-1

Siritho, 2015, The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients, Mult Scler J, 22, 964, 10.1177/1352458515614093

Yan, 2016, Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD, Sci China Life Sci, 59, 1270, 10.1007/s11427-015-4997-y

Woodhall, 2013, Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica, J Neurol Sci, 335, 221, 10.1016/j.jns.2013.08.034

Melamed, 2015, Update on biomarkers in neuromyelitis optica, Neurol Neuroimmunol Neuroinflamm, 2, e134, 10.1212/NXI.0000000000000134

Pandit, 2015, Demographic and clinical features of neuromyelitis optica: a review, Mult Scler J, 21, 845, 10.1177/1352458515572406

Jarius, 2016, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement – frequency, presentation and outcome, J Neuroinflamm, 13, 281, 10.1186/s12974-016-0719-z

Spadaro, 2016, Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis, Neurol Neuroimmunol Neuroinflamm, 3, e257, 10.1212/NXI.0000000000000257

Amano, 2014, Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report, BMC Neurol, 14, 224, 10.1186/s12883-014-0224-x

Nakamura, 2017, Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report, BMC Neurol, 17, 76, 10.1186/s12883-017-0858-6

Jarius, 2016, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin, J Neuroinflamm, 13, 279, 10.1186/s12974-016-0717-1

Pröbstel, 2011, Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis, Neurology, 77, 580, 10.1212/WNL.0b013e318228c0b1

Ramanathan, 2015, Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis, Mult Scler, 22, 470, 10.1177/1352458515593406

Akaishi, 2016, MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study, J Neurol Neurosurg Psychiatry, 87, 446, 10.1136/jnnp-2014-310206

Pache, 2016, MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients, J Neuroinflamm, 13, 282, 10.1186/s12974-016-0720-6

Stiebel-Kalish, 2017, Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study, PLoS One, 12, e0170847, 10.1371/journal.pone.0170847

Sepúlveda, 2016, Neuromyelitis optica spectrum disorders. Comparison according to the phenotype and serostatus, Neurol Neuroimmunol Neuroinflamm, 3, e225, 10.1212/NXI.0000000000000225

Baumann, 2016, Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases, Mult Scler, 22, 1821, 10.1177/1352458516631038

Hacohen, 2015, Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children, Neurol Neuroimmunol Neuroinflamm, 2, e81, 10.1212/NXI.0000000000000081

Ketelslegers, 2015, Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort, Mult Scler J, 4, 1, 10.1177/1352458514566666

Fernandez-Carbonell, 2015, Clinical and MRI phenotype of children with MOG antibodies, Mult Scler J, 22, 174, 10.1177/1352458515587751

Di Pauli, 2011, Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases, Clin Immunol, 138, 247, 10.1016/j.clim.2010.11.013

Mayer, 2013, Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases, J Immunol, 191, 3594, 10.4049/jimmunol.1301296

Oshiro, 2016, [Anti-MOG + neuromyelitis optica spectrum disorders treated with plasmapheresis], No To Hattatsu, 48, 199, 10.11251/ojjscn.48.199

Papadopoulos, 2014, Treatment of neuromyelitis optica: state-of-the-art and emerging therapies, Nat Rev Neurol, 10, 493, 10.1038/nrneurol.2014.141

Nakajima, 2015, Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis, BMJ Open, 5, e007766, 10.1136/bmjopen-2015-007766

Bonnan, 2012, Plasma exchange in severe attacks of neuromyelitis optica, Mult Scler Int, 2012, 1, 10.1155/2012/787630

Nozaki, 2006, Fulminant Devic disease successfully treated by lymphocytapheresis, J Neurol Neurosurg Psychiatry, 77, 1094, 10.1136/jnnp.2005.086306

Shimizu, 2010, IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum, Neurology, 75, 1423, 10.1212/WNL.0b013e3181f8832e

Kim, 2012, Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?, Mult Scler, 18, 1480, 10.1177/1352458512439439

Barnett, 2012, Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy, Mult Scler, 18, 108, 10.1177/1352458511421185

Kitley, 2014, Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab, J Neurol Sci, 339, 223, 10.1016/j.jns.2014.01.035

Min, 2012, Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder, Mult Scler, 18, 113, 10.1177/1352458511431973

Izaki, 2013, [A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment], Clin Neurol, 53, 513, 10.5692/clinicalneurol.53.513